Sugi Predict

Sugi Predict / Compounds / SCHEMBL1577091

SCHEMBL1577091

SCHEMBL1577091

CCOC(=O)[C@H]1C[C@H](C)CCN1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPM1B O75688 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PPP1CC P36873 1/20 0.36
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ MAPT P10636 4/20 0.35
▸ PRCP P42785 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8578784 1.00 PPM1B (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
SCHEMBL28471905 1.00 PPM1B (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
SCHEMBL29041638 1.00 PPM1B (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
SCHEMBL3664884 1.00 PPM1B (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
SCHEMBL28464081 1.00 PPM1B (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
Hydrochloric Acid SCHEMBL5956124 0.98 KDM4E (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
Hydrochloric Acid SCHEMBL12985786 0.98 KDM4E (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
Hydrochloric Acid SCHEMBL18259765 0.98 KDM4E (0.36) PPM1BPTPN1PPP1CCTRPM8MAPT
Hydrochloric Acid SCHEMBL28222584 0.86 SOAT1 (0.40) TRPM8MAPTPRCPKDM4ECYP1A2
SCHEMBL10963921 0.85 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114605494-B Argatroban and preparation method of intermediate thereof 江苏美迪克化学品有限公司 2024-06-04 — — CN claimed
CN-116478085-B Method for resolution synthesis of argatroban intermediate (2R, 4R) -4-methyl-2-ethyl piperidine formate 浙江康聚药业有限公司 2023-11-07 — — CN claimed
CN-116478085-A Method for resolution synthesis of argatroban intermediate (2R, 4R) -4-methyl-2-ethyl piperidine formate 浙江康聚药业有限公司 2023-07-25 — — CN claimed
CN-114705790-B Detection method of ethyl (2R, 4R) -4-methyl-2-piperidinecarboxylate isomer 石家庄四药有限公司 2022-11-01 — — CN claimed
CN-115124458-A Preparation method of novel thrombin inhibitor 天津羲泽润科技有限公司 2022-09-30 — — CN claimed
CN-114705790-A Detection method of ethyl (2R,4R) -4-methyl-2-piperidinecarboxylate isomer 石家庄四药有限公司 2022-07-05 — — CN claimed
CN-114605494-A Preparation method of argatroban and intermediate thereof 江苏美迪克化学品有限公司 2022-06-10 — — CN claimed
CN-212016984-U Argatroban intermediate reaction liquid filtering device 安庆恩聚生物医药科技有限公司 2020-11-27 — — CN claimed
CN-111961114-A Argatroban intermediate and preparation method and application thereof 扬州中宝药业股份有限公司 2020-11-20 — — CN claimed
CN-211463151-U Reaction vessel is used in production of argatroban midbody 安庆恩聚生物医药科技有限公司 2020-09-11 — — CN claimed
US-9994526-B2 Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) 2018-06-12 — — US claimed
US-20160347711-A1 PROCESS INTERMEDIATES AND METHODS FOR THE PREPARATION OF PROCESS INTERMEDIATES FOR THE SYNTHESIS OF ARGATROBAN MONOHYDRATE LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) 2016-12-01 — — US claimed
EP-2694493-B1 METHOD FOR THE PREPARATION OF PROCESS INTERMEDIATES FOR THE SYNTHESIS OF ARGATROBAN MONOHYDRATE LUNDBECK PHARMACEUTICALS ITALY S P A (IT) 2015-06-17 — — EP claimed
EP-0823430-B1 Method for preparing n2-arylsulfonyl-l-argininamides MITSUBISHI CHEM CORP (JP) 2001-10-24 — — EP claimed
US-5925760-A Method for preparing N2 -arylsulfonyl-L-argininamides MITSUBISHI CHEMICAL CORPORATION (JP) 1999-07-20 — — US claimed
EP-0823430-A1 Method for preparing n2-arylsulfonyl-l-argininamides MITSUBISHI CHEMICAL CORPORATION (JP) 1998-02-11 — — EP claimed
CN-120483909-A Argatroban middle Process for the preparation of intermediates 合肥拓锐生物科技有限公司 2025-08-15 — — CN disclosed
CN-118684618-A Argatroban middle Process for the preparation of intermediates 山东新时代药业有限公司 2024-09-24 — — CN disclosed
WO-1995013274-A1 ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES PFIZER LIMITED (GB) 1995-05-18 — — WO disclosed
CN-1100143-A Enzymatic resolution of 2-piperidinecarboxylic acid alkyl esters and use of the products obtained SYNTHELABO (FR) 1995-03-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347711-A1 PROCESS INTERMEDIATES AND METHODS FOR THE PREPARATION OF PROCESS INTERMEDIATES FOR THE SYNTHESIS OF ARGATROBAN MONOHYDRATE DHPS, MMAB, AMD1 PPM1B 3147/4885PTPN1 4868/4885PPP1CC 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.